A recent report by PMLiVE offers a look at the U.K.’s recent drug pricing deal introduced in January, the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
The arrangement, according to the report, addresses patient access to some medicines. Value assessment is also a key component to the deal.
The National Institute for Health and Care Excellence (NICE) will also assess new active substances in their first indications, as well as any major indications that may follow.
To read the full report on PMLiVE, click here.